3647 results for «686»
3647 results
Top Innovations
20 Nov 2023 – From PCR London Valves 2023
Discover the future of cardiac care with these 3 top innovations! ARTERY, revolutionizing structural heart treatment, Vesalius Transfemoral DMR Repair, combining chordal and annular support in one-transfemoral device, and Approxima, a right ventricular reshaping device, offering a fresh perspective on tricuspid regurgitation.
Rapid-fire - Complex structural interventions
20 Nov 2023 – From PCR London Valves 2023
Explore groundbreaking cases in this session: choosing septal coiling over alcohol septal ablation in hypertrophic cardiomyopathy, managing a giant LAA with two Watchman Devices, treating a complex pseudoaneurysm in a patient with cardiogenic shock, and more!
Novel indications for DCB
21 May 2026 – From EuroPCR 2026
This session reviews emerging clinical applications for drug-coated balloons (DCB) beyond traditional indications. It covers outcomes in venous stenosis, aorto-ostial lesions, and coronary bifurcation disease, comparing DCB strategies with drug-eluting stents and highlighting recent clinical trial findings.
Refining PCI plannings and decision-making with novel technologies
21 May 2026 – From EuroPCR 2026
This session highlights cutting-edge technologies that enhance PCI planning and decision-making. It covers the clinical populations benefiting from QFR-guided revascularisation, prognostic insights from radial wall strain in DCB-treated vessels, and advances in artificial intelligence and machine learning to assess ischemia and predict PCI outcomes, especially in...
A randomised trial comparing imaging-guided PCI with Orsiro vs Xience
18 May 2021
Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...
Authors :
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation
05 Sep 2023
Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.
Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...
Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...
Author
